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Background-—Silent brain infarcts (SBIs) are highly prevalent in the aged population and relate to the occurrence of further stroke
and dementia. Serum N-glycome levels have been previously associated with aging and they might be related as well to the
presence of SBIs and age-related white matter hyperintensities.
Methods and Results-—We determined the serum N-glycome proﬁle in a cohort study comprising 972 subjects and evaluated the
relationship between N-glycome levels and the presence and number of SBIs and with age-related white matter hyperintensities
grades, assessed by brain magnetic resonance imaging. Decreasing concentrations of bigalacto core-a-1,6-fucosylated biantennary
glycan and increasing concentrations of branching a-1,3-fucosylated triantennary glycan remained as independent predictors of
SBIs (odds ratio 0.4, 95% CI 0.3–0.7 and odds ratio 1.8, 95% CI 1–3.2, respectively), after controlling for the presence of age and
classic vascular risk factors. A similar pattern was found to be related to an increasing number of SBIs and white matter
hyperintensities grade.
Conclusions-—N-glycome levels might be potentially useful as biomarkers for the presence of silent cerebrovascular disease.
( J Am Heart Assoc. 2015;4:e002669 doi: 10.1161/JAHA.115.002669)
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T he term “silent brain infarcts” (SBIs) refers to cerebralinfarcts that are found incidentally on neuroimaging,
particularly brain magnetic resonance imaging (MRI), in the
absence of symptoms suggesting a corresponding stroke
event. The majority of SBIs are truly silent, but they can also
be associated with subtle symptoms, neurological abnormal-
ities, and cognitive impairment. More importantly, individuals
with SBIs have a 2- to 4-fold higher risk of having a future
stroke or dementia than patients without them, independently
of the presence of other vascular risk factors. Thus, they may
also be referred to as “covert infarcts” or “MRI-deﬁned
infarcts,” rather than “silent.” Their prevalence in population-
based studies ranges from 8% to 28% of healthy individuals.
They are 5 times more frequent than stroke and therefore
they constitute a signiﬁcant burden of brain vascular disease.1
The majority of silent brain infarcts are lacunar infarcts and
they usually coexist with other markers of cerebral small
vessel disease, as white matter hyperintensities (WMHs).2
Age is the more clearly identiﬁed risk factor for SBIs, and
according to a systematic review, the odds ratio for prevalent
SBIs assessed per year of age ranges from 1.03 to 1.13 (or
from 2.44–3.21 per decade). As a consequence, and given the
progressive aging of the population in developed countries,
the prevalence and consequences of SBIs are expected to
reach epidemic proportions in the near future. Despite these
numbers, their systematic screening is not recommended
(brain MRI is expensive and its availability is limited in some
settings). The use of plasma biomarkers for their identiﬁcation
could potentially overcome these limitations and help clini-
cians to establish preventive treatments to decrease the
burden of stroke and dementia.
We have previously shown that urine albumin-to-creatinine
ratio (or microalbuminuria) and lipoprotein-associated phos-
pholipase A2 (Lp-PLA2) are associated with the risk of SBIs in
hypertensive individuals. Subjects with microalbuminuria had
twice the odds of SBIs, while Lp-PLA2 activity was also
associated with the presence of SBIs, but only in women.3,4
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Other potentially interesting candidate biomarkers would
be N-glycans. N-glycans are oligosaccharide structures cova-
lently linked (sugar–amino acid linkage) to an asparagine
residue of a protein in a consensus sequence (GlcNAc-b-Asn).
These sugar structures are highly heterogeneous and their
biosynthesis is closely linked to the cellular metabolism,
thereby they reﬂect the metabolic status of cells. They were
ﬁrst described in relation to aging in 1988, when their proﬁle
in plasma G immunoglobulins were studied in a group of 151
subjects.5 Later on, the entire serum N-glycome was inves-
tigated and a consistent pattern of changes in the N-glycan
structures related to age was described within different
European and Asian populations.6,7 N-glycome levels have
also been described in relation to neurodegenerative diseases
such as Alzheimer disease.8,9
In the present study, we hypothesized that the serum
glycome proﬁle might reﬂect “brain aging” as well, and could
be helpful for the identiﬁcation of SBIs or other silent brain
vascular lesions, such as WMHs.
Speciﬁcally in this study, we evaluated whether the serum
N-glycome relates to SBIs (and WMHs) and additionally, we
assessed their predictive value independently of other clinical
parameters and previously described biological markers to
detect SBIs in a large cohort of stroke-free individuals.
Methods
Study Population
Subjects for this study are those included within the ISSYS
(Investigating Silent Strokes in hYpertensives: a magnetic
resonance imaging Study). The basic design of this study is a
cohort study in a randomly selected sample of 976 hyper-
tensive individuals, aged 50 to 70 years old, with no history of
previous clinical stroke or dementia. This study is aimed to
determine the prevalence of silent brain infarcts and to assess
their determinants. All participants were recruited in the city
of Barcelona. A stratiﬁed randomization method was used to
control for age, sex, and the center from which the subjects
were recruited. Additional details on subject selection and
baseline procedures have been published elsewhere.4,10
Participants with prior stroke were excluded after it was
conﬁrmed by medical records and in those reporting sugges-
tive stroke symptoms, according to the Stroke Symptom
questionnaire.11 Other exclusion criteria were (1) impossibility
to undergo a brain MRI (ie, patients carrying pacemakers,
cochlear stimulators, etc), (2) suspected white coat hyper-
tension syndrome, and (3) short-term life expectancy pre-
venting follow-up examinations.
On baseline, clinical data were collected, including demo-
graphic and personal medical history, and the presence of
vascular risk factors or an established cardiovascular disease.
Systolic and diastolic ofﬁce BP was measured with an
oscillometric device (Omron M6 Comfort), and the mean of
the last 2 of 3 determinations after 5-minute rest was
recorded. Diabetes mellitus was deﬁned as fasting glucose
levels over 7 mmol/L and/or the use of oral antidiabetic
drugs or insulin. Smoking habit was collected and categorized
into current, former, or never. Alcohol abuse was deﬁned as
intake of at least 280 g/week in males and 170 g/week in
females. Body mass index was calculated as weight (kg)
divided by height squared (m2). Coronary artery disease was
recorded in participants with history of angina, myocardial
infarction, or in those who underwent percutaneous coronary
interventions or coronary artery bypass graft. Previous
cardiovascular disease included coronary artery disease and
peripheral artery disease (intermittent claudication, bypass
surgery, aortic aneurysm).
This study was approved by our local institutional review
Ethics Committee, and all subjects gave their informed
consent to participate prior to the inclusion.
Brain MRI
A brain MRI with a pre-established data acquisition protocol
was performed within the next month after study entry. All
examinations were performed with the same 1.5 Tesla MR
(Signa HDx 1.5, General Electrics, Waukesha, WI), including
axial T1, T2, and ﬂuid-attenuated inversion recovery weighted
images.
SBIs were deﬁned as previously,12 as lesions of ≥3 mm in
their widest diameter, with cerebrospinal ﬂuid–like signal
characteristics in all pulse sequences, and with a hyperin-
tense rim surrounding the lesion in ﬂuid-attenuated inversion
recovery MRI. These lesions were differentiated from enlarged
perivascular spaces based on their size, shape, and location.
SBIs were dichotomized into 2 categories (present/absent)
and also the number of SBIs was considered in our study.
WMHs were rated at ﬂuid-attenuated inversion recovery
and deﬁned as extensive or focal lesions that appeared as
hyperintense lesions in the white matter (WM). They were
graded in the subcortical deep WM and in periventricular
regions, according to the Fazekas scale.13 For the analysis we
considered WMHs as signiﬁcant when lesions scored at least
2 points in this scale in the periventricular regions (ie, smooth
halo or irregular lesions extending into the deep WM) or deep
WM (ie, beginning of conﬂuent foci or large conﬂuent areas).
All images were primarily assessed by 2 neuroradiologists
and in a second term by the same readers plus an
experienced stroke neurologist. They were blinded to labora-
tory measurements and clinical data. Intrarater agreement
was calculated for each reader in a training set before
undertaking the present reading. Both intra- and inter-rater
agreement between different observers and imaging features
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ranged from 0.60 to 0.75. Disagreements in assessments
were solved by consensus. Representative examples of these
MRI features are shown in Figure 1.
N-glycome Proﬁle Assessment
On the baseline visit of the ISSYS study, blood samples were
obtained in all participants. Peripheral venous samples were
collected in tubes with no anticoagulant and serum was
extracted after 15-minute centrifugation (1500 g) and then
frozen at 80°C until the test was performed.
N-glycan proﬁles were generated from 2-lL serum samples
by DSA-FACE (DNA Sequencer Adapted-Fluorophore Assisted
Carbohydrate Electrophoresis) technology using a capillary
electrophoresis (CE)-based ABI3130 Genetic Analyzer
(Applied Biosystems, Foster City, CA). Samples were only
tested once since the intra- and interassay coefﬁcients of
variation of the glycan analyses have been reported previously
to be <5%.6 Results are normalized values from peaks 1 to 9,
which represent relative concentrations of the oligosaccha-
rides that are more prominent in humans. Brieﬂy, the
corresponding structures are as follows: peak 1 corresponds
to agalacto core-a-1,6-fucosylated biantennary glycan
(NGA2F); peak 2, to agalacto core-a-1,6-fucosylated bisecting
biantennary glycan (NGA2FB); peak 3 and peak 4 to single
agalacto core-a-1,6-fucosylated biantennary glycans
(NG1A2F); peak 5, to bigalacto biantennary glycan (NA2);
peak 6, to bigalacto core-a-1,6-fucosylated biantennary
glycan (NA2F); peak 7, to bigalacto core-a-1,6-fucosylated
bisecting biantennary glycan (NA2FB); peak 8, to triantennary
glycan (NA3); and peak 9, to branching a-1,3-fucosylated
triantennary glycan (NA3Fb).7 (Figure 2).
In the same participants, we assayed serum total and high-
density lipoprotein cholesterol (Olympus, Lismeehan, Ireland)
and Lp-PLA2 activity (PLAC test for activity, Diadexus, Inc)
using enzyme assays on a single automated clinical chemistry
analyzer (Olympus AU 2700). Finally, a single spot urine
sample was also collected at the baseline visit and sent to a
central laboratory for determining the urinary albumin-
to-creatinine ratio.3,4 Microalbuminuria was deﬁned as the
presence of urinary albumin-to-creatinine ratio higher than
21 mg/g in men and over 30 mg/g in women.14
Statistical Analyses
For descriptive purposes, normality for continuous variables
was assessed by the Kolmogorov–Smirnov test. None of the
N-glycans structures was normally distributed in our sample,
except NA2. For univariate analysis, continuous variables
were compared using t test and ANOVA or Mann–Whitney U
test and Kruskal–Wallis test when appropriate. Categorical
variables were compared using Pearson v2 and continuous
data were analyzed using Pearson or Spearman correlation,
depending on their distribution. We studied how the serum
N-glycome proﬁle related to age, to the presence of traditional
vascular risk factors, and to the presence/absence of SBIs
Figure 1. Representative examples of imaging markers of cere-
bral small-vessel disease. From left to right: Brain infarct affecting
caudate nuclei is shown by a white arrow (FLAIR MRI), extensive
white matter changes (FLAIR MRI), 1.5 Tesla MR (Signa HDx 1.5;
General Electric, Waukesha, WI). FLAIR indicates ﬂuid-attenuated
inversion recovery; MRI, magnetic resonance imaging.
Figure 2. Typical human serum N-glycome proﬁle, and struc-
tural formulas of N-glycans. Peak 1 is an agalactosylated, core-a-
1,6-fucosylated biantennary glycan (NGA2F), peak 2 is an
agalactosylated, core-a-1,6-fucosylated bisecting biantennary
(NGA2FB), peaks 3 and 4 are monogalactosylated, core-a-1,6-
fucosylated biantennary (NG1A2F), peak 5 is a bigalactosylated,
biantennary glycan (NA2), peak 6 is a bigalactosylated, core-a-
1,6-fucosylated biantennary (NA2F), peak 7 is a bigalactosylated,
core-a-1,6-fucosylated bisecting biantennary (NA2FB), peak 8 is a
trigalactosylated, tri-antennary (NA3), peak 9 is a branching a-1,3-
fucosylated trigalactosylated tri-antennary (NA3F(b) [Lewis X Ag:
GlcNac-galactose-fucose]).
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and their number (considering 3 categories: none versus
single versus multiple).
False discovery rate correction was applied for multiple
comparisons and statistical signiﬁcance was set at P values
<0.05.
To assess for independent associations between
N-glycome structures and SBIs, adjusted models were
constructed by means of forward stepwise logistic regression
analysis including as covariates potential confounders such as
age, sex, diastolic blood pressure, diabetes mellitus, tobacco,
and high-density lipoprotein cholesterol. Additionally, we
added in the models Lp-PLA2 activity and the presence of
microalbuminuria, since both of them have been related to
SBIs in our cohort before. Odds ratios and 95% CI will be
presented.
To assess the improvement to prediction by adding
variables (in this case, the serum N-glycome structures) to
a logistic regression model, likelihood ratio tests were used
(Using R version 3.1.0 “Spring dance” software [Copyright
(C) 2014 The R Foundation for Statistical Computing]).15
Also, we provided measures of global diagnostic accuracy
for SBIs detection (area under the receiver operator curves)
of the different models including or not the information
on the serum N-glycome and compared them by using
the Delong’s method16 implemented at MedCalc 12.4
software.
Finally, 2 more exploratory analyses were performed. First,
we sought associations between serum N-glycome levels and
other brain vascular lesions, speciﬁcally with the presence of
signiﬁcant WMHs at subcortical deep and periventricular
areas. Secondly, we studied whether the N-glycome
correlated with other markers that we previously related to
SBIs (microalbuminuria and Lp-PLA2), both in univariate and
adjusted linear regression models (considering as outcomes
the changes observed in the N-glycome).
Results
We obtained results on the serum N-glycome proﬁle in almost
all participants from the ISSYS study (n=972, 99.6%). Median
age of the participants was 64 (59–67) years old and 59.4%
were males. Other baseline clinical characteristics of the
sample are shown in Table 1.
Serum N-glycome Proﬁle, Age, and Vascular Risk
Factors
As previously described, several N-glycans were associated
with age in this population (NGA2F, NGA2FB, NA2F, and NA3).
Speciﬁcally, a weak positive correlation was observed with
age for NGA2F and NGA2FB (r=0.14, P<0.001 and r=0.17,
P<0.001, respectively), whereas a negative correlation was
found for NA2F and NA3 (r=0.12, P<0.001 and r=0.06,
P=0.051). Also, as described before, age was correlated with
the log ratio of NGA2F to NA2F or GlycoAgeTest (r=0.17,
P<0.001) (also named GlycoAgeTest).6
Associations between different N-Glycans and demo-
graphic and cardiovascular risk factors are shown in Table 2.
Signiﬁcant differences were observed among some of the
peaks regarding sex, vascular risk factors such as diabetes,
dyslipidemia, and tobacco and alcohol intake. Moreover, some
Table 1. Description of Demographic and Clinical Baseline Factors in the Total Sample and in Those With or Without SBIs
Included Patients (n=972) Absence of SBI (n=874) Presence of SBI (n=98) P Value
Age, y 64 (59–67) 64 (58–67) 65 (62–68) 0.001
Sex, female 50.5% 53% 28.6% <0.001
Diabetes mellitus 23.5% 22.8% 29.6% 0.13
HDL cholesterol 47.5 (40–57) 47.9 (40.3–57.4) 44.6 (39–51.9) <0.001
Mean SBP, mm Hg 142 (132–153) 142 (132–153) 142 (131–152) 0.76
Mean DBP, mm Hg 789 789 8010 0.02
Tobacco use 15.1% 15.3% 13.3% 0.59
Alcohol abuse 6.5% 6.7% 4.8% 0.79
Any established CVD 12.3% 11.2% 22.4% 0.001
CAD 6.7% 8.7% 18.6% 0.002
LpPLA2 activity, nmol/mL per minute 181 (153–215) 179 (151–215) 195.5 (158–232) 0.03
Microalbuminuria 12.9% 11.5% 26.4% <0.001
Data are expressed in median (interquartile range), meanSD, and percentage as appropriate. CAD indicates coronary artery disease; CVD, cardiovascular disease; DBP, diastolic blood
pressure; HDL, high-density lipoproteins; Lp-PLA2, lipoprotein-associated phospholipase A2; SBI, silent brain infarct; SBP, systolic blood pressure.
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peaks were associated with obesity measurements such as
body mass index or waist circumference.
Serum N-glycome Proﬁle and SBIs
From all participants with valid data on serum N-glycome, 98
subjects presented 1 or more SBIs on MRI (10.1%). Among all
factors associated with SBIs in the univariate analysis
(Table 1) and as reported before,4 age, male sex, and the
presence of microalbuminuria were independent predictors of
SBIs in our sample.
Regarding the serum N-glycome, we found that NA2F and
NA3Fb were associated in opposite directions with the
presence of SBIs, as shown in Figure 3A. NA2F and NA3Fb
were also associated with the multiplicity of SBI (comparing
none, single infarct, and multiple infarcts) as shown in
Figure 3B. Furthermore, in order to evaluate whether these
associations were independent of age, the presence of other
risk factors, and potential confounders, we performed logistic
regression analysis. In order to do so, cutoffs for these peaks
were selected based on their sensitivity and speciﬁcity on
SBIs diagnosis, determined by conﬁguring receiver operator
characteristics curves (NA2F≤16.66: sensitivity=50%, speci-
ﬁcity=67% and NA3Fb≥2.11: sensitivity=79.6%, speci-
ﬁcity=38.6%). As shown in Table 3, both N-glycan structures
remained as independent predictors of SBIs in fully adjusted
models, together with increasing age, male sex, increasing
diastolic blood pressure, and the presence of microalbumin-
uria.
Moreover, the addition of these serum N-glycans to the
clinical model was signiﬁcantly associated with an improve-
ment on the prediction of SBIs (v2 of the likelihood ratio
Figure 3. Boxplots representing the relation between NA2F and NA3Fb and the presence (A) and number (B) of SBIs. NA2F:
bigalacto core-a-1,6-fucosylated biantennary glycan; NA3Fb: branching a-1,3-fucosylated triantennary glycan. *P<0.01.
Whiskers were calculated by the formula (Q1-1.5 [interquartile range]) and (Q3-1.5 [interquartile range]). NA2F indicates peak
6, to bigalacto core-a-1,6-fucosylated biantennary glycan; NA3Fb, peak 9, to branching a-1,3-fucosylated triantennary glycan;
SBIs, silent brain infarcts.
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test=11.394, P value <0.001), and with a nonsigniﬁcant
increase in the global diagnostic accuracy (area under the
curve increased from 69.2% to 72.6%, P=0.083). The area
under the curve of the model containing only clinical variables
plus Lp-PLA2 and the presence of microalbuminuria was also
smaller (ie, less predictive capacity) than the fully adjusted
model containing the N-glycome structures (area under the
curve=70.1%).
Regarding other brain vascular lesions, such as WMH, we
found the same N-glycan structures (P value=0.012 for NA2F,
and P value=0.015 for NA3Fb) related to the presence of
signiﬁcant WMHs at the periventricular areas, whereas no
associations between the serum N-glycome and WMH at deep
subcortical areas were observed. In this case, only NA2F
remained independently associated with the presence of
signiﬁcant periventricular WMHs (odds ratio considering
NA2F≤16.66=0.47, from 0.30–0.74, P=0.001) together with
age (odds ratio per year increase=1.12, 1.07–1.18, P<0.001)
and the mean diastolic blood pressure (odds ratio per mm Hg
increase=1.04, 1.02–1.07, P=0.001).
Finally, we conducted an exploratory analysis to evaluate
how the biomarkers associated with SBIs in the ISSYS study
(Lp-PLA2 activity, microalbuminuria, and NA2F and NA3Fb)
were related to each other. We found that NA3Fb was
signiﬁcantly higher in those with microalbuminuria (2.95
[2.11–3.90] versus 2.49 [1.71–3.48], P<0.05), whereas NA2F
was positively correlated with Lp-PLA2 activity (Spearman
R=0.221, P value<0.001). However, these associations were
no longer present after we controlled for age, sex, or smoking
habit, suggesting that they were not independent from the
existence of vascular risk factors.
Discussion
In this study, we described for the ﬁrst time that the serum
N-glycome relate to the presence of silent brain lesions (SBIs,
WMHs), independently of age and of the presence of vascular
risk factors. To our knowledge, this is the ﬁrst study
investigating serum N-glycans as markers of silent cere-
brovascular disease. Remarkably, they were independent of
age, which is the main risk factor for these conditions, and
also from other biological markers, such as the presence of
microalbuminuria and Lp-PLA2 activity levels.
We have described that relative concentrations of
N-glycans are related to traditional vascular risk factors in
our population. These ﬁndings are in agreement with the
results from a Croatian population study that reported the
relationship of different N-glycans with several vascular risk
factors such as age, sex, smoking, lipid levels, and body fat
measurements. As in our case, age and vascular risk factors
explained only a small amount of the variability in the
N-glycan proﬁle, that otherwise has been strongly associated
with the genetic background and/or speciﬁc physiopatholog-
ical conditions.17
An increasing number of studies have investigated the role
of blood biomarkers associated with age-related WMHs in the
past and a smaller number focused on SBIs, but very few of
them have been replicated in other populations thus far.18 The
most well-known biomarkers are related to inﬂammation and
endothelial dysfunction: C-reactive protein,19 interleukin-6,20
homocysteine,21 and urinary albumin-to-creatinine ratio or
microalbuminuria.22
Despite the heterogeneous set of proteins and lipids to
which N-glycans structures can be attached, previous reports
have described speciﬁc patterns in relation to several
pathological conditions, such as NA2 for nonalcoholic
steatohepatitis,23 NA2FB for liver cirrhosis,24 NA3Fb for
hepatocellular carcinoma25 or NG1A2F for type 2 diabetes
mellitus.26
In our study, even though sensitivity and speciﬁcity of
NA2F and NA3Fb cutoff values were low, they improved
prediction of SBIs when added to affordable clinical variables,
Table 3. Association of N-glycome Structures with SBIs in the Multivariate Analysis
Variables
Model 1 Model 2 Model 3
OR (95% CI) OR (95% CI) OR (95% CI)
Age per 1-year increase 1.09 (1.05–1.14) 1.08 (1.03–1.13) 1.08 (1.03–1.13)
Sex, male 2.84 (1.77–4.57) 2.61 (1.58–4.32) 2.5 (1.46–4.28)
Mean office DBP per 1 mm Hg increase 1.03 (1.00–1.05) ns 1.3 (1.00–1.05)
Microalbuminuria — 2.50 (1.45–4.31) 1.87 (1.04–3.36)
NA2F≥16.657 — — 0.42 (0.26–0.69)
NA3Fb>2.1134 — — 1.81 (1.00–3.28)
Model 1 is adjusted by age, sex, mean (DBP), diabetes, tobacco, and high-density lipoprotein cholesterol. Model 2 is additionally adjusted by microalbuminuria and lipoprotein-associated
phospholipase A2 activity nmol/mL per minute. Model 3 includes the same covariates as model 2 plus the relative amounts of NA2F and NA3Fb below and above their calculated cutoffs.
ns, means ofﬁce DBP was not included in model 2. DBP indicates diastolic blood pressure; NA2F, peak 6, to bigalacto core-a-1,6-fucosylated biantennary glycan; NA3Fb, peak 9, to
branching a-1,3-fucosylated triantennary glycan; OR, odds ratio; SBI, silent brain infarct.
DOI: 10.1161/JAHA.115.002669 Journal of the American Heart Association 7
N-glycans and Small Vessel Disease Vilar-Bergua et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
but the diagnostic accuracy of these models (72.6%) still
needs to be enhanced to be more accurate and useful from a
clinical point of view as surrogate. Possibly this can be
achieved by combining them with other biological markers
involved in different molecular pathways, and including all
possible interactions among all biomarkers might also be a
key aspect in the analyses. Indeed, the study of several
biomarkers contained in a single panel seems to be a
promising strategy to diagnose SBIs, as others have reported
before. As examples, a panel of biomarkers involving inﬂam-
mation, hemostasis, neurohormonal activity, and endothelial
function was described to be associated with subclinical
vascular brain lesions.27 More recently, Shoamanesh and
collaborators tested a panel of 15 markers related to systemic
inﬂammation, vascular inﬂammation, and oxidative stress and
found differential associations of these markers with hemor-
rhagic (cerebral microbleeds) and ischemic (WMHs and SBIs)
manifestations of cerebral small vessel disease.28
Interestingly, we found a different N-glycome proﬁle
concerning SBIs and WMHs and additionally, N-glycans were
only related to periventricular but not deep WMHs. This might
be relevant, since it is uncertain whether or not periventricular
and deep WMHs differ regarding pathogenesis, risk factors,
and clinical consequences.29
Our study has some strengths and limitations. As
strengths, it has been performed in a large cohort and we
obtained results on serum N-glycans in almost the whole
original sample, limiting selection biases. Also, we described
the serum N-glycan levels as risk factors for SBIs and other
brain vascular lesions such as WMHs and assessed their
diagnostic accuracy over clinical features and other previously
described biological markers.
This study also has some limitations.
The major sources of N-glycosylated proteins in serum are
the B-cells (immunoglobulins), but other cells such as
macrophages (cytokines) and other cell types can also
contribute. It is well known that small changes in the cell
environment can be associated with large changes in the
N-glycans produced by a cell type.30 Therefore, the
N-glycosylation patterns that we described here associated
with SBIs and white matter hyperintensities might be
signatures of changes in the structure and function of
proteins involved in cerebrovascular disease, suggesting that
they could be promising markers to identify speciﬁc thera-
peutic targets and for their future use as biomarkers.
Conclusions
We have measured and described for the ﬁrst time an
association between the serum N-glycome and SBIs in a large
cohort of stroke-free individuals. If validated in other samples
and combined with other biomarkers in a panel, these
N-glycans could be useful to assess the risk of cerebral small
vessel disease in asymptomatic individuals.
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